Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

A New Option in Hormone Receptor-Positive Breast Cancer: Fulvestrant and Dovitinib

A New Option in Hormone Receptor-Positive Breast Cancer: Fulvestrant and Dovitinib

The development of targeted smart drugs has brought personalized treatment to disseminated (stage 4, metastatic) cancers. Hormone-sensitive disseminated breast cancer is a successful example.

Genetic analyses of cancer cells identify features in some patients that may cause treatment resistance from the outset. Approximately %70 of breast cancers are hormone-dependent. In this cancer, hormone-suppressing treatment after a certain period, resistance can develop. Fibroblast growth factor receptor 1 (FGFR1) is a pathway activating tumor growth and allowing cancer cells to evade cell death (the apoptosis pathway). FGFR1 overproliferation may occur in %8 of hormone receptor-positive breast cancers.

breast cancer types luminal a b her2 positive triple negative hormone estrogen and proge

The Study A study enrolled menopausal patients previously receiving hormonal treatment whose disease had progressed, with breast cancer diagnosed in 97 participants. Those with overactive FGFR1 received the estrogen receptor suppressor fulvestrant together with the FGFR inhibitor dovitinib .

Dovitinib provided an additional 5,5 months until progression and increased overall response, with no side-effect difference compared with the untreated placebo arm.

This study represents a promising new approach for patients developing hormonal treatment resistance. We will follow future results and American FDA approval processes.

Sources

A Musolino, M Campone, P Neven et al.
Phase II, Randomized, Placebo-Controlled Study of Dovitinib in Combination With Fulvestrant in Postmenopausal Patients With HR(+), HER2(−) Breast Cancer That Had Progressed During or After Prior Endocrine Therapy.
Breast Cancer Res 2017 Feb 10;19(1)18

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

A New Option in Hormone Receptor-Positive Breast Cancer: Fulvestrant and Dovitinib

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy